Page 81 - Haematologica July
P. 81
Exosomal miRNAs in AA and MDS
31. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exo- somes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3.22.
32. Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014; 30(4):523-530.
33. Dweep H, Gretz N. miRWalk2.0: a com- prehensive atlas of microRNA-target inter- actions. Nat Methods. 2015;12(8):697.
34. Dumontet, C, Drai J, Bienvenu J, et al. Profiles and prognostic values of lactate dehydrogenase iso-enzymes in patients with non-hodgkin's lymphoma. Leukemia. 1999;13(5):811-817.
35. Oliveros JC. Venny. An interactive tool for comparing lists with Venn's diagrams. (2007-2015). Available from: http:// bioin- fogp.cnb. csic.es/tools/venny/ index. html
36. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hor- mones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467-477.
37. Mosakhani N, Räty R, Tyybäkinoja A, Karjalainen-Lindsberg ML, Elonen E, Knuutila S. MicroRNA profiling in
chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res. 2013;141(4):272-276.
38. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS. Regulation of RUNX3 tumor suppressor gene expression in cuta- neous melanoma. Clin Cancer Res. 2009;15(9):2988-2994.
39. Montagner S, Dehó L, Monticelli S. MicroRNAs in hematopoietic develop- ment. BMC Immunol. 2014;15:14.
40. Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007;449(7164):919-922.
41. Tan G, Wu L, Tan J, et al. MiR-1180 pro- motes apoptotic resistance to human hepa- tocellular carcinoma via activation of NF- B signaling pathway. Sci Rep. 2016;6:22328.
42. Chan B, Manley J, Lee J, Singh SR. The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 2015;356(2 Pt A):301-308.
43. Ebrahimi F, Gopalan V, Smith RA, Lam AK. miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol. 2014;96(1):98-107.
44. Lechman ER, Gentner B, Ng SW, et al. miR- 126 Regulates Distinct Self-Renewal
Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell. 2016;29(2):214-228.
45. Tomasetti M, Monaco F, Manzella N, et al. MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma. Oncotarget. 2016; 7(24):36338-36352.
46. Zhong P, Zhang J, Cui X. Abnormal metabolites related to bone marrow failure in aplastic anemia patients. Genet Mol Res. 2015;14(4):13709-13718.
47. Manier S, Liu CJ, Avet-Loiseau H, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129(17):2429-2436.
48. Bockmeyer CL, Säuberlich K, Wittig J, et al. Comparison of different normalization strategies for the analysis of glomerular microRNAs in IgA nephropathy. Sci Rep. 2016;6:31992.
49. Witwer KW, Buzás EI, Bemis LT, et al. Standardization of sample collection, isola- tion and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2.
50. Narita A, Kojima S. Biomarkers for predict- ing clinical response to immunosuppressive therapy in aplastic anemia. Int J Hematol. 2016;104(2):153-158.
haematologica | 2018; 103(7)
1159
